Shattuck Labs (NASDAQ:STTK) Director Clay Siegall Acquires 62,500 Shares

Shattuck Labs, Inc. (NASDAQ:STTK) Director Clay Siegall bought 62,500 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were bought at an average cost of $4.00 per share, for a total transaction of $250,000.00. Following the transaction, the director directly owned 318,608 shares of the company’s stock, valued at $1,274,432. This trade represents a 24.40% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shattuck Labs Price Performance

STTK stock traded up $0.05 on Thursday, reaching $4.18. 916,353 shares of the company were exchanged, compared to its average volume of 687,374. Shattuck Labs, Inc. has a 12 month low of $0.71 and a 12 month high of $8.33. The stock’s fifty day moving average price is $6.42 and its 200 day moving average price is $4.93. The firm has a market capitalization of $320.53 million, a PE ratio of -6.63 and a beta of 1.08.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. During the same quarter in the prior year, the business posted ($0.27) EPS. As a group, research analysts expect that Shattuck Labs, Inc. will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Shattuck Labs

A number of institutional investors have recently bought and sold shares of the business. Orbimed Advisors LLC acquired a new stake in Shattuck Labs during the third quarter worth $15,072,000. NEXTBio Capital Management LP acquired a new stake in Shattuck Labs during the fourth quarter worth $11,497,000. Price T Rowe Associates Inc. MD acquired a new stake in Shattuck Labs during the fourth quarter worth $7,031,000. Pinnacle Associates Ltd. boosted its stake in Shattuck Labs by 1.8% during the third quarter. Pinnacle Associates Ltd. now owns 1,388,723 shares of the company’s stock worth $3,319,000 after buying an additional 25,000 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in Shattuck Labs during the fourth quarter worth $4,945,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Shattuck Labs in a research report on Monday, April 27th. They set an “overweight” rating on the stock. Wedbush boosted their target price on shares of Shattuck Labs from $8.00 to $11.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Wall Street Zen downgraded shares of Shattuck Labs from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings downgraded shares of Shattuck Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 2nd. Finally, Needham & Company LLC lifted their price target on shares of Shattuck Labs from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Shattuck Labs presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.